4232. Fondaparinux Sodium

Nomenclature

CAS number: 114870-03-0
Methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-d-glucopyranosyl-(1→4)-O-β-d-glucopyranuronosyl-(1→4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-d-glucopyranosyl-(1→4)-O-2-O-sulfo-α-l-idopyranuronosyl(1→4)-2-deoxy-2-(sulfoamino)-α-d-glucopyranoside 6-(hydrogen sulfate) decasodium salt; fondaparin sodium; SR-90107A; Org-31540; IC-851589; Arixtra (GSK).
C31H43N3Na10O49S8; mol wt 1728.08.
C 21.55%, H 2.51%, N 2.43%, Na 13.30%, O 45.37%, S 14.84%.

Description and references

Synthetic pentasaccharide corresponding to the antithrombin binding site of heparin, q.v. Prepn: M. Petitou et al., EP 84999; eidem, US 4818816 (1983, 1989 both to Choay); M. Petitou et al., Carbohydr. Res. 167, 67 (1987). Review of pharmacology: J. M. Herbert et al., Cardiovasc. Drug Rev. 15, 1-26 (1997). Clinical pharmacokinetics: B. Boneu et al., Thromb. Haemostasis 74, 1468 (1995). Clinical trial for prevention of post-operative deep-vein thrombosis: A. G. G. Turpie et al., N. Engl. J. Med. 344, 619 (2001). Clinical comparison with enoxaparin, q.v. in treatment of established deep-vein thrombosis: H. R. Büller et al., Ann. Intern. Med. 140, 867 (2004). Review of clinical safety and efficacy: A. G. G. Turpie, Expert Opin. Drug Saf. 4, 707-721 (2005).

Chemical structure

Properties

White powder after lyophilisation. [α]D23 +48° (c = 0.61 in water).

Therapeutic Category

Antithrombotic.

Keywords

Antithrombotic